Although prosurvival shifts within the BCL-2 family have been reported in CML and a number of pre-clinical combinations of TKIs with BH3 mimetics have been carried out and display promise [16], comparisons of BH3 mimetic responses within BP-CML are few. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.